Cargando…
In Utero Oxcarbazepine Exposure and Neonatal Abstinence Syndrome: Case Report and Brief Review of the Literature
Oxcarbazepine is a second‐generation antiepileptic drug that is used to treat partial seizures. Although it has been increasingly used in pregnant women, its fetal safety has not been fully validated. We describe a 12‐hour‐old neonate who developed neonatal abstinence syndrome (NAS) after intrauteri...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5575550/ https://www.ncbi.nlm.nih.gov/pubmed/28543284 http://dx.doi.org/10.1002/phar.1955 |
_version_ | 1783260070170066944 |
---|---|
author | Chen, Chao‐yang Li, Xing Ma, Ling‐yue Wu, Peng‐hui Zhou, Ying Feng, Qi Cui, Yi‐min |
author_facet | Chen, Chao‐yang Li, Xing Ma, Ling‐yue Wu, Peng‐hui Zhou, Ying Feng, Qi Cui, Yi‐min |
author_sort | Chen, Chao‐yang |
collection | PubMed |
description | Oxcarbazepine is a second‐generation antiepileptic drug that is used to treat partial seizures. Although it has been increasingly used in pregnant women, its fetal safety has not been fully validated. We describe a 12‐hour‐old neonate who developed neonatal abstinence syndrome (NAS) after intrauterine exposure to oxcarbazepine. The neonate was born via cesarean section to a mother who took oxcarbazepine 300 mg/day for treatment of seizures throughout her pregnancy. Approximately 12 hours after birth, the infant developed paroxysmal jitter, which mainly presented as increased excitability, irritability, limb shaking, and increased muscle tone. These symptoms resolved by day 9 of life. Although NAS occurs most often after in utero exposure to opioids, exposure to other drugs during pregnancy may contribute to a small proportion of NAS cases. To our knowledge, this is the second case report of oxcarbazepine‐induced NAS. Pregnant women with epilepsy should weigh the pros and cons of continuing oxcarbazepine during their pregnancy when they are prescribed this drug. For infants with in utero oxcarbazepine exposure, comprehensive assessments and examinations are necessary for screening oxcarbazepine‐induced NAS. |
format | Online Article Text |
id | pubmed-5575550 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-55755502017-09-18 In Utero Oxcarbazepine Exposure and Neonatal Abstinence Syndrome: Case Report and Brief Review of the Literature Chen, Chao‐yang Li, Xing Ma, Ling‐yue Wu, Peng‐hui Zhou, Ying Feng, Qi Cui, Yi‐min Pharmacotherapy Case Report Oxcarbazepine is a second‐generation antiepileptic drug that is used to treat partial seizures. Although it has been increasingly used in pregnant women, its fetal safety has not been fully validated. We describe a 12‐hour‐old neonate who developed neonatal abstinence syndrome (NAS) after intrauterine exposure to oxcarbazepine. The neonate was born via cesarean section to a mother who took oxcarbazepine 300 mg/day for treatment of seizures throughout her pregnancy. Approximately 12 hours after birth, the infant developed paroxysmal jitter, which mainly presented as increased excitability, irritability, limb shaking, and increased muscle tone. These symptoms resolved by day 9 of life. Although NAS occurs most often after in utero exposure to opioids, exposure to other drugs during pregnancy may contribute to a small proportion of NAS cases. To our knowledge, this is the second case report of oxcarbazepine‐induced NAS. Pregnant women with epilepsy should weigh the pros and cons of continuing oxcarbazepine during their pregnancy when they are prescribed this drug. For infants with in utero oxcarbazepine exposure, comprehensive assessments and examinations are necessary for screening oxcarbazepine‐induced NAS. John Wiley and Sons Inc. 2017-07-02 2017-07 /pmc/articles/PMC5575550/ /pubmed/28543284 http://dx.doi.org/10.1002/phar.1955 Text en © 2017 The Authors. Pharmacotherapy published by Wiley Periodicals, Inc. on behalf of Pharmacotherapy Publications, Inc. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Case Report Chen, Chao‐yang Li, Xing Ma, Ling‐yue Wu, Peng‐hui Zhou, Ying Feng, Qi Cui, Yi‐min In Utero Oxcarbazepine Exposure and Neonatal Abstinence Syndrome: Case Report and Brief Review of the Literature |
title | In Utero Oxcarbazepine Exposure and Neonatal Abstinence Syndrome: Case Report and Brief Review of the Literature |
title_full | In Utero Oxcarbazepine Exposure and Neonatal Abstinence Syndrome: Case Report and Brief Review of the Literature |
title_fullStr | In Utero Oxcarbazepine Exposure and Neonatal Abstinence Syndrome: Case Report and Brief Review of the Literature |
title_full_unstemmed | In Utero Oxcarbazepine Exposure and Neonatal Abstinence Syndrome: Case Report and Brief Review of the Literature |
title_short | In Utero Oxcarbazepine Exposure and Neonatal Abstinence Syndrome: Case Report and Brief Review of the Literature |
title_sort | in utero oxcarbazepine exposure and neonatal abstinence syndrome: case report and brief review of the literature |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5575550/ https://www.ncbi.nlm.nih.gov/pubmed/28543284 http://dx.doi.org/10.1002/phar.1955 |
work_keys_str_mv | AT chenchaoyang inuterooxcarbazepineexposureandneonatalabstinencesyndromecasereportandbriefreviewoftheliterature AT lixing inuterooxcarbazepineexposureandneonatalabstinencesyndromecasereportandbriefreviewoftheliterature AT malingyue inuterooxcarbazepineexposureandneonatalabstinencesyndromecasereportandbriefreviewoftheliterature AT wupenghui inuterooxcarbazepineexposureandneonatalabstinencesyndromecasereportandbriefreviewoftheliterature AT zhouying inuterooxcarbazepineexposureandneonatalabstinencesyndromecasereportandbriefreviewoftheliterature AT fengqi inuterooxcarbazepineexposureandneonatalabstinencesyndromecasereportandbriefreviewoftheliterature AT cuiyimin inuterooxcarbazepineexposureandneonatalabstinencesyndromecasereportandbriefreviewoftheliterature |